Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae

International Journal of Antimicrobial Agents

Volumn 41, Issue 6, 2013, Pages 582-585

  Wiskirchen, Dora E ^a   Crandon, Jared L ^b   Nicolau, David P ^b  

^a UNIVERSITY OF SAINT JOSEPH   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Doripenem; Ertapenem; KPC

Indexed keywords

CARBAPENEMASE; DORIPENEM; ERTAPENEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; INSTITUTE FOR CANCER RESEARCH MOUSE; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TREATMENT DURATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; IMMUNOCOMPROMISED HOST; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICE, INBRED ICR; NEUTROPENIA; TREATMENT OUTCOME;

EID: 84877700761     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.02.015     Document Type: Article

References (15)

1. E.B. Hirsch, and V.H. Tam Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection J Antimicrob Chemother 108 2010 1119 1125
2. L.B. Gasnik, P.H. Edelstein, E. Lautenbach, M. Synnestvedt, and N.O. Fishman Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae Infect Control Hosp Epidemiol 30 2009 1180 1185
3. C.C. Bulik, and D.P. Nicolau Double carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae Antimicrob Agents Chemother 55 2011 3002 3004
4. R.A. Keel, P.R. Tessier, J.L. Crandon, and D.P. Nicolau Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model Antimicrob Agents Chemother 56 2012 4403 4407
5. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M07-A8. Wayne, PA; 2008.
6. C.C. Bulik, and D.P. Nicolau In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase-producing Klebsiella pneumoniae Antimicrob Agents Chemother 54 2010 4112 4115
7. D. Xuan, M.A. Banevicius, B. Capitano, M.K. Kim, C. Nightingale, and D.P. Nicolau Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model Antimicrob Agents Chemother 46 2002 2990 2995
8. C.A. Deryke, M.A. Banevicius, H.W. Fan, and D.P. Nicolau Bactericidal activities of meropenem and ertapenem against extended-spectrum-β- lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model Antimicrob Agents Chemother 51 2007 1481 1486
9. K.S. Thomson Double-carbapenem therapy not proven to be more active than carbapenem monotherapy against KPC-positive Klebsiella pneumoniae Antimicrob Agents Chemother 56 2012 4037
10. G.L. Daikos, and A. Markogiannakis Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 17 2011 1135 1141
11. M. Chen, A.N. Nafziger, G.L. Drusano, L. Ma, and J.S. Bertino Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults Antimicrob Agents Chemother 50 2006 1222 1227
12. D.E. Wiskirchen, P. Koomanachai, A.M. Nicasio, D.P. Nicolau, and J.L. Kuti In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase Antimicrob Agents Chemother 55 2011 1420 1427
13. C. Urban, N. Mariano, and J.J. Rahal In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli Antimicrob Agents Chemother 54 2010 2732 2734
14. Z.A. Qureshi, D.L. Paterson, B.A. Potoski, M.C. Kilayko, G. Sandovsky, and E. Sordillo Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens Antimicrob Agents Chemother 56 2012 2108 2113
15. M. Tumbarello, V. Pierluigi, C. Viscoli, E.M. Trecarichi, F. Tumietto, and A. Marchese Predictors of mortality in bloodstream infections caused by KPC-producing Klebsiella pneumoniae: importance of combination therapy Clin Infect Dis 55 2012 943 950